Market ripe for Bluebird IPO, other first-time public offerings
This article was originally published in Scrip
The public markets are ripe for biopharma financing as investors continue to pluck fruit from the growing field of drug developers with initial public offerings, including recent IPO filers Iroko Pharmaceuticals, Conatus Pharmaceuticals and Onconova Therapeutics.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.